Cite
Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation.
MLA
Go Itakura, et al. “Controlling Immune Rejection Is a Fail-Safe System against Potential Tumorigenicity after Human IPSC-Derived Neural Stem Cell Transplantation.” PLoS ONE, vol. 10, no. 2, Jan. 2015, p. e0116413. EBSCOhost, https://doi.org/10.1371/journal.pone.0116413.
APA
Go Itakura, Yoshiomi Kobayashi, Soraya Nishimura, Hiroki Iwai, Morito Takano, Akio Iwanami, Yoshiaki Toyama, Hideyuki Okano, & Masaya Nakamura. (2015). Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation. PLoS ONE, 10(2), e0116413. https://doi.org/10.1371/journal.pone.0116413
Chicago
Go Itakura, Yoshiomi Kobayashi, Soraya Nishimura, Hiroki Iwai, Morito Takano, Akio Iwanami, Yoshiaki Toyama, Hideyuki Okano, and Masaya Nakamura. 2015. “Controlling Immune Rejection Is a Fail-Safe System against Potential Tumorigenicity after Human IPSC-Derived Neural Stem Cell Transplantation.” PLoS ONE 10 (2): e0116413. doi:10.1371/journal.pone.0116413.